SOPHiA GENETICS has announced a collaboration with Unilabs to deploy the SOPHiA DDM Platform across Unilabs' network in Switzerland, which will test for HRD status in solid tumors and provide expedited analysis.

HRD is caused by a cell's inability to repair DNA through the homologous recombination repair (HRR) pathway and is the most prevalent alteration in ovarian cancer. SOPHiA DDM's AI-based technology analyzes and interprets raw data using next-generation sequencing (NGS) to provide reliable HRD results for personalized treatment planning.

Unilabs is a Switzerland-based provider of clinical laboratory testing and medical diagnostic imaging services across Europe. One of its major expansions included a merger with Capio Diagnostics in 2007, reaching into Sweden, Norway, Finland, Denmark, and the UK​. Unilabs’ services include laboratory medicine, cellular pathology, and medical imaging